Patents by Inventor Timothy Sproul

Timothy Sproul has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8680247
    Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Glypican-3 with high affinity. Nucleic acid molecules encoding Glypican-3 antibodies, expression vectors, host cells and methods for expressing the Glypican-3 antibodies are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the Glypican-3 antibodies are also provided. Methods for detecting Glypican-3, as well as methods for treating various Glypican-3-related conditions, including hepatocellular cancer, are disclosed.
    Type: Grant
    Filed: July 17, 2008
    Date of Patent: March 25, 2014
    Assignee: Medarex, L.L.C.
    Inventors: Jonathan Alexander Terrett, Li-Sheng Lu, Haichun Huang, Dapeng Yao, Chin Pan, Heidi Leblanc, Timothy Sproul, Mark Yamanaka
  • Publication number: 20100209432
    Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Glypican-3 with high affinity. Nucleic acid molecules encoding Glypican-3 antibodies, expression vectors, host cells and methods for expressing the Glypican-3 antibodies are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the Glypican-3 antibodies are also provided. Methods for detecting Glypican-3, as well as methods for treating various Glypican-3-related conditions, including hepatocellular cancer, are disclosed.
    Type: Application
    Filed: July 17, 2008
    Publication date: August 19, 2010
    Applicant: MEDAREX, INC.
    Inventors: Jonathan Alexander Terrette, Li-sheng Lu, Haichun Huang, Dapeng Yao, Chin Pan, Heidi Leblanc, Timothy Sproul, Mark Yamanaka